Observational Study of Golimumab Intravenous Infusion

Sponsor
Janssen Inc.
Study ID
NCT02390700
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Golimumab Intravenous — BIOLOGICAL
    This is a non-interventional study. Participants with rheumatoid arthritis in Canada will be observed for 24 months.

Study Details

The purpose of this study is to evaluate the incidence and management of infusion reactions with Golimumab intravenous infusion.

Key Dates

Start date
Feb 28, 2015
Status verified
Nov 2016
Primary completion
Oct 31, 2016
Completion
Oct 31, 2016

Study Design

Enrollment
78 participants (actual)

Arms

  • Arm: Golimumab Intravenous
    Participants with rheumatoid arthritis (RA) in Canada, will be observed for 24 months. Only data available from source documentation will be collected.

Primary Outcome Measure

Number of Participants With Infusion Reactions [ Time Frame: Up to end of study (2 years) or early withdrawal ]

Related Studies